[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-vaccine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-vaccine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,76,104,131,155,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100631238","digital-interventions-to-increase-hpv-vaccination-intentions-among-nigerian-caregivers-100631238",false,"NCT07498075","Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","Inclusion Criteria:\n\n* Parent or primary caregiver of at least one girl aged 9-14 years\n* Parent states \"no\" or \"unsure\" to question asking if eligible daughter has received any doses of the HPV vaccine\n* Provides informed consent to participate\n\nExclusion Criteria:\n\n* Parent or caregiver of a girl who has already received one or more doses of the HPV vaccine\n* Does not meet age eligibility criteria for an eligible daughter\n* Fails Attention Checks",true,"ALL","27 Years",{"count":20,"type":21},3340,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low.\n\nParents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, (3) a set of short edutainment videos about HPV vaccination, (4) standard informational infographics about HPV vaccination from a national public health agency, or (5) unrelated health content about menstruation.\n\nThe main outcome is parents' self-reported intention to vaccinate their daughter against HPV, measured immediately and one week after exposure to the assigned content. Additional outcomes include HPV-related knowledge, perceptions of vaccine safety, willingness to recommend the vaccine to others, and self-reported vaccine uptake at 1-week and 6 month follow-up. The results will help inform scalable communication strategies to improve HPV vaccination uptake in low- and middle-income settings.",[27,28],"HPV","HPV Vaccine",[27,28,30,31,32],"Chatbots","Misinformation","Pre-Bunking","NOT_YET_RECRUITING","2026-05-18",{"date":36,"type":37},"2026-05-20","ACTUAL",{"date":34,"type":21},{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"University of Pennsylvania","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100621979","phase-2-strengthening-hpv-immunization-through-epi-leveraged-delivery-100621979","NCT07377656","Strengthening HPV Immunization Through EPI Leveraged Delivery","A Randomized, Observer-Blind, Placebo-Controlled, Proof-of-Concept Study to Assess the Safety, Tolerability and Immunogenicity of a Bivalent Human Papillomavirus (HPV) Vaccine in 9 and 15 Month Old Infants and Toddlers, 2-5 Year Old Children and an Open Label Single Dose Study in Young Unmarried Females Aged 15-20 Years in Ghana","SHIELD","Inclusion Criteria:\n\n* Healthy male and female individuals aged 9 months, 15 months, 2-5 years and unmarried females aged 15-20 years at the time of vaccination\n* Participants aged 9 months, 15 months and 2-5 years who are up to date with their EPI vaccinations.\n* Residing within the area of the study and planning to stay for the study duration.\n* Participants that are HIV negative at screening (for the 9-15-month-olds a documented negative maternal ANC HIV screening).\n* Unmarried females with a negative pregnancy test at screening practicing\u002Fwilling to practice continuous effective contraception as recommended by the Ghana Health Services guidance in Ghana\n* Able and willing to comply with all study requirements.\n* Willingness to provide written informed consent before any trial procedure. Assent will be required for young female participants aged 15-17 years at vaccination in addition to their parent's\u002FLAR's consent.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy, lactation, or intention to become pregnant during the vaccination phase through three months after the study vaccine dose\n* Previous vaccination against HPV (Only for the 15-20-year-old efficacy cohort)\n* Presence of malnutrition (weight-for-length z-score ≤-2SD median, per WHO published child growth standards)\n* Planning to migrate out of the study areas before the end of the study follow-up\n* Any underlying known condition or criteria, including acute or chronic clinically significant abnormality or infection that in the opinion of the investigator might compromise the wellbeing of the participant or interfere with the outcome of the study.\n* Administration of immunoglobulins and\u002F or any blood products within the three months preceding the administration of the study vaccine.\n* Known history of allergy or anaphylaxis to study vaccine components and\u002For excipients or other medications, or any other allergies deemed by the investigator to increase the risk of an adverse reaction.\n* Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent severe infections and chronic use (more than 14 days) of immunosuppressant medication within 3 months prior to recruitment (topical steroids may be allowed).\n* Any other finding that in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor-quality data.","9 Months","20 Years",{"count":55,"type":21},115,[57],"PHASE2","This is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9- and 15-month-olds) comparing them to an immune-bridging population of 15-20-year-old unmarried females in an open label study in Ghana at the Dodowa Health Research Center.",[28],[27,61,62,50,63,64,65,66],"Proof of concept","Ghana","IVI","International Vaccine Institute","Karolinska Institutet","Dodowa Health Research Center","RECRUITING","2026-05-14",{"date":34,"type":37},{"date":71,"type":37},"2026-04-30",{"date":73,"type":21},"2028-12-31",{"name":64,"class":43},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100604943","phase-4-persistence-of-immune-response-six-years-after-one-dose-of-9vhpv-vaccine-among-male-and-female-students-100604943","NCT07156084","Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students","CIRN-HPV-ONE","Inclusion Criteria:\n\n* Have received a single dose of 9vHPV vaccine at ages 9-11 during the school year 2019-2020;\n* Not have received any other HPV vaccine doses;\n* Be able to consent to the study.\n\nExclusion Criteria:\n\n* Immunosuppressed (at recruitment or when immunized).","15 Years","17 Years",{"count":86,"type":21},300,[88],"PHASE4","Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program.\n\nLittle data on the immunogenicity (antibody production) and long-term efficacy of a single dose of the vaccine are available, particularly in boys.\n\nThe primary objective of this study is to assess the persistence of HPV antibodies six years after the administration of a single dose of the 9vHPV vaccine to students aged 9 to 11 years in Grade 4 in 2019-2020.\n\nThe study will be conducted at the CHU de Québec-Université Laval research center.\n\nRecruitment is conducted through school service centers in the Quebec City region. Youth who received only a single dose of the 9vHPV vaccine at the ages of 9-11 in 2019-2020 will be eligible to participate.\n\nApproximately 300 youth will take part in this study: 150 girls and 150 boys.\n\nParticipants will have to answer few questions about their health to ensure their eligibility for the study. For eligible participants consenting to participate a 10 ml (\\\u003C1 tablespoon) blood sample will be taken.",[28],[27,92,93],"Vaccination","Schedule","2025-09-24",{"date":96,"type":37},"2025-09-29",{"date":98,"type":37},"2025-09-23",{"date":100,"type":21},"2026-02",{"name":102,"class":103},"Canadian Immunization Research Network","NETWORK",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":111,"minAge":83,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100608362","evaluation-of-a-vaccine-chatbot-on-hpv-vaccine-confidence-and-hesitancy-100608362","NCT07200570","Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy","Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy: a Randomized Controlled Trial and Implementation Science Study","Inclusion Criteria:\n\n* Female, aged 15 to 26 years, inclusive.\n* Not previously vaccinated against HPV.\n* Reports no contraindications to HPV vaccination.\n* Has no mental, visual, or reading impairments that would preclude cooperation with study activities.\n* Is willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Male.\n* Age under 15 or over 26 years.\n* Has a history of prior HPV vaccination.\n* Has a known contraindication to HPV vaccination.\n* Unable to comply with study procedures.\n* Is unwilling or unable to provide informed consent.","FEMALE","26 Years",{"count":114,"type":21},1800,[24],"The goal of this clinical trial is to learn if a chatbot powered by artificial intelligence works to improve HPV vaccination among females aged 15 to 26 in China. A randomized controlled trial and implementation science study will be conducted targeting females as participants. The main questions it aims to answer are:\n\n1. Does the vaccine chatbot influence women's confidence, literacy, hesitancy, and uptake of the HPV vaccine.\n2. What are the public acceptance of chatbot and the facilitators and barriers to its implementation in a real-world setting.\n\nResearchers will compare a group of women who use the chatbot with a group who do not use it to see if the chatbot is effective at helping women feel confident and willing to get vaccinated against HPV.\n\nParticipants will:\n\n1. Be recruited and randomly allocated into one of two groups. One group will be invited to use the HPV vaccine chatbot and the other group will not get access to the vaccine chatbot until the end of the trial.\n2. Complete a questionnaire survey on their confidence, literacy, and hesitancy on the HPV vaccine.\n3. Have their vaccination status checked at the end of trial.",[28],[27,119,120,121,122],"vaccine confidence","chatbot","randomised controlled trial","implementation science",{"date":124,"type":37},"2025-10-01",{"date":126,"type":21},"2025-09-26",{"date":128,"type":21},"2026-05",{"name":130,"class":43},"Fudan University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":27,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":75},"100580025","hpv-ends-here-increasing-uptake-of-the-hpv-vaccine-100580025","NCT06831929","HPV Ends Here: Increasing Uptake of the HPV Vaccine","Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents","Inclusion Criteria:\n\n• Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine\n\nExclusion Criteria:\n\n• Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.","10 Years","12 Years",{"count":141,"type":21},2232,[24],"Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design.",[28],[27,146],"Human Papillomavirus","2025-04-22",{"date":149,"type":37},"2025-04-25",{"date":151,"type":37},"2025-02-28",{"date":40,"type":21},{"name":154,"class":43},"University of California, Davis",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":111,"minAge":138,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100533582","effectiveness-of-vaccine-chatbot-on-hpv-vaccine-awareness-and-vaccination-in-china-100533582","NCT06227689","Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China","Evaluation of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination for Middle School Girls in China: a Randomized Controlled Trial and Implementation Science Study","Inclusion Criteria:\n\n* Parents of female students in middle school;\n* The students not vaccinated or appointed for HPV vaccination and without contraindications to HPV vaccines;\n* Without mental disorders or visual\u002Freading impairments, and able to cooperate with and undergo the intervention activities;\n* Obtained informed consent and willing to participate in the study.\n\nExclusion Criteria:\n\n* Students vaccinated or appointed for HPV vaccination or with any contraindication to HPV vaccines;\n* With mental disorders or visual\u002Freading impairments, and unable to cooperate with and undergo the intervention activities;\n* Unwilling to participate.","16 Years",{"count":114,"type":21},[24],"This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are:\n\n1. How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge of HPV vaccines, their willingness to vaccinate their daughters, and vaccination status of female students.\n2. How is the vaccine chatbots accepted by all stakeholders, and what are the facilitators of and barriers to implementing vaccine chatbot promotion campaign.\n\nThe intervention group will go through the intervention measure while the control group will not:\n\n1. The intervention group will be invited to use the HPV vaccine chatbot online through WeChat , the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.\n2. The control group will not use the chatbot during the intervention duration.\n\nResearchers will compare participants' HPV vaccine awareness, and vaccination intention and status after intervention between intervention group and control group to evaluate if the vaccine chatbot improves HPV vaccine awareness and vaccination.",[28],[168,169,170,171,119],"HPV vaccine","awareness","knowledge","vaccination","2024-06-10",{"date":174,"type":37},"2024-06-12",{"date":176,"type":37},"2024-01-18",{"date":178,"type":21},"2024-07-31",{"name":130,"class":43},2,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":16,"sex":111,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":75},"100526638","two-domestic-hpv-vaccines-and-imported-hpv-vaccines-in-women-aged-13-14-years-study-on-immunogenicity-100526638","NCT06137352","Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity","Two Domestic HPV Vaccines (Wozehui ® and Cecolin ®) and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity：A Multi-center Cohort Study in China","Inclusion Criteria:\n\n* Participants who have completed all procedures of domestic bivalent HPV vaccine or imported HPV vaccine and are 30-60 days from the last dose of vaccination at the time of enrollment;\n* The participants are between 13-14 years old at the time of the first dose of domestic or imported HPV vaccination;\n* The participant himself\u002Fherself and his\u002Fher guardian are able to provide proof of legal identity;\n* The participant and his\u002Fher guardian are capable of understanding and signing the informed consent form;\n* Participants are willing to complete study-related follow-up visits and blood collection as required by the protocol.\n\nExclusion Criteria:\n\n* Participants who have received other marketed HPV vaccines, or who have participated in clinical studies of HPV vaccines, or who have participated in clinical studies of other vaccines within the last 6 months;\n* Participants with congenital malformations, developmental disorders, genetic defects, and severe malnutrition that are severe or cause damage to vital organs;\n* Participants with a history of epilepsy, psychosis, and major depression requiring medication, convulsions or seizures or a family history of psychosis;\n* Participants who are immune compromised or have been diagnosed with congenital or acquired immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Rheumatoid - - Arthritis, Juvenile Rheumatoid Arthritis (JRA), Inflammatory Bowel Disease (IBD), or other autoimmune disease, subjects who have received immunosuppressive therapy within the past 6 months;\n* Absence of spleen, functional absence of spleen, and subjects with any condition resulting in absence of spleen or splenectomy;\n* Subjects with physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders;\n* Participants who, in the judgment of the investigator, have any other factors that make them unsuitable for participation in a clinical trials.","13 Years","14 Years",{"count":191,"type":21},3000,"OBSERVATIONAL","This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women aged 13-14 years. A total of 3,000 subjects who have completed 2 doses of the domestic bivalent HPV vaccine and 3 doses of the imported HPV vaccine will be recruited from Fujian Maternal and Child Health Hospital as the initiator of the study, and will be recruited from a number of healthcare institutions nationwide. Of these, 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Wozehui), 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Cecolin), and 1,000 subjects were vaccinated with the imported HPV vaccine. Each subject was enrolled within 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and a total of two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine. In response to the WHO Cervical Cancer Elimination Strategy, domestic bivalent HPV vaccine has been offered free of charge to adolescent females aged 13-14 years, but there is still a lack of evidence comparing the antibody titer levels of domestic HPV vaccine and imported HPV vaccine in younger females. Therefore, we conducted the present immunogenicity study to explore the immunogenicity and immune persistence after vaccination with domestic bivalent HPV vaccine versus imported HPV vaccine in this age group of females.",[195,28,196],"HPV Infection","Cervical Cancer Prevention","2023-11-16",{"date":199,"type":37},"2023-11-18",{"date":201,"type":21},"2023-12-15",{"date":40,"type":21},{"name":204,"class":43},"Fujian Maternity and Child Health Hospital"]